The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PI3 kinase. Also provided in the present invention are methods of using these compositions to modulate activities of one or more of these kinases, especially for therapeutic applications.
HETEROBICYCLIC CARBOXAMIDES AS INHIBITORS FOR KINASES
申请人:ARTMANN, III Gerald David
公开号:US20120245187A1
公开(公告)日:2012-09-27
The invention relates to novel organic compounds of formula (I)
and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
Heterobicyclic Carboxamides as inhibitors for kinases
申请人:Artmann, III Gerald David
公开号:US20100168082A1
公开(公告)日:2010-07-01
The invention relates to novel organic compounds of formula (I)
and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumour diseases and ocular neovascular diseases.
Heterobicyclic carboxamides as inhibitors for kinases
申请人:Novartis AG
公开号:US08242125B2
公开(公告)日:2012-08-14
The invention relates to novel organic compounds of formula (I)
and their use in the treatment of the animal or human body, to pharmaceutical compositions comprising a compound of formula I and to the use of a compound of formula I for the preparation of pharmaceutical compositions for use in the treatment of protein kinase dependent diseases, especially of proliferative diseases, such as in the treatment of tumor diseases and ocular neovascular diseases.